p18 INK4C (DCS118) Mouse mAb



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

ity	0.02% sodium azide. S	dium HEPES (pH 7.5		Dilution 1:1000 1:50			
ity	0.02% sodium azide. S						
ity	The p18 INK4C (DCS11		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μ g/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.				
	does not cross-react w	•	ects endogenous levels of the INK4 family.	of p18 INK4C prote	in. The antibody		
n	Monoclonal antibody is produced by immunizing animals with purified recombinant human p18 INK4C protein.						
	CDK4 and CDK6 assoc phosphorylation is a r include p15 INK4B, p1 haploinsufficient tumo motifs and selectively amino-terminal portio of INK4 family membe	ciate with the D-type necessary event for 6 INK4A, p18 INK40 or suppressor <i>in vi</i> u inhibit CDK4/6 action of the fourth ank ers can be a binary	e cyclins and phosphoryl cells to enter S-phase (1 C and p19 INK4D. p18 ha o (2). All INK4 proteins a vity. Mutational analyses cyrin repeat in mediating complex with CDK4/6 or	ate the retinoblast). The inhibitors of the is been shown to fure re composed of 32 of p18 implicate the binding to CDK4/6 ternary complex w	oma protein. This CDK4 (INK4) family inction as a amino acid ankyring third and the (3). The interaction		
nces	1. Lukas, J. et al. (1996) <i>Mol. Cell. Biol.</i> 16, 6917-6925. 2. Bai, F. et al. (2003) <i>Mol. Cell. Biol.</i> 23, 1269-1277. 3. Noh, S.J. et al. (1999) <i>Cancer Res.</i> 59, 558-564. 4. Guan, K.L. et al. (1994) <i>Genes Dev.</i> 8, 2939-2952. 5. Hirai, H. et al. (1995) <i>Mol. Cell. Biol.</i> 15, 2672-2681.						
1	nces	Cyclin-dependent kina CDK4 and CDK6 assoc phosphorylation is a r include p15 INK4B, p1 haploinsufficient tume motifs and selectively amino-terminal portic of INK4 family membe CDK4/6 and ultimately 1. Lukas, J. et al. (1996 2. Bai, F. et al. (2003) / 3. Noh, S.J. et al. (1995 4. Guan, K.L. et al. (1995	Cyclin-dependent kinases (CDKs) are active CDK4 and CDK6 associate with the D-type phosphorylation is a necessary event for include p15 INK4B, p16 INK4A, p18 INK4b haploinsufficient tumor suppressor <i>in viv</i> motifs and selectively inhibit CDK4/6 actively and a selectively inhibit CDK4/6 actively inhibit CDK4/6 actively inhibit CDK4/6 actively inhibit CDK4/6 and ultimately results in the inhibit CDK4/6 and ultimately results in the inhibit color i	Cyclin-dependent kinases (CDKs) are activated in part by forming CDK4 and CDK6 associate with the D-type cyclins and phosphoryl phosphorylation is a necessary event for cells to enter S-phase (1 include p15 INK4B, p16 INK4A, p18 INK4C and p19 INK4D. p18 ha haploinsufficient tumor suppressor <i>in vivo</i> (2). All INK4 proteins a motifs and selectively inhibit CDK4/6 activity. Mutational analyses amino-terminal portion of the fourth ankyrin repeat in mediating of INK4 family members can be a binary complex with CDK4/6 or CDK4/6 and ultimately results in the inhibition of cell cycle progres 1. Lukas, J. et al. (1996) <i>Mol. Cell. Biol.</i> 16, 6917-6925. 2. Bai, F. et al. (2003) <i>Mol. Cell. Biol.</i> 23, 1269-1277. 3. Noh, S.J. et al. (1999) <i>Cancer Res.</i> 59, 558-564. 4. Guan, K.L. et al. (1994) <i>Genes Dev.</i> 8, 2939-2952.	Cyclin-dependent kinases (CDKs) are activated in part by forming complexes with cyclin-dependent kinases (CDKs) are activated in part by forming complexes with cyclins and CDK6 associate with the D-type cyclins and phosphorylate the retinoblastic phosphorylation is a necessary event for cells to enter S-phase (1). The inhibitors of include p15 INK4B, p16 INK4A, p18 INK4C and p19 INK4D. p18 has been shown to full haploinsufficient tumor suppressor <i>in vivo</i> (2). All INK4 proteins are composed of 32 motifs and selectively inhibit CDK4/6 activity. Mutational analyses of p18 implicate the amino-terminal portion of the fourth ankyrin repeat in mediating binding to CDK4/6 of INK4 family members can be a binary complex with CDK4/6 or ternary complex with CDK4/6 and ultimately results in the inhibition of cell cycle progression (4,5). 1. Lukas, J. et al. (1996) <i>Mol. Cell. Biol.</i> 16, 6917-6925. 2. Bai, F. et al. (2003) <i>Mol. Cell. Biol.</i> 23, 1269-1277. 3. Noh, S.J. et al. (1999) <i>Cancer Res.</i> 59, 558-564. 4. Guan, K.L. et al. (1994) <i>Genes Dev.</i> 8, 2939-2952. 5. Hirai, H. et al. (1995) <i>Mol. Cell. Biol.</i> 15, 2672-2681.		

Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat

dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key W: Western Blotting IP: Immunoprecipitation

Cross-Reactivity Key H: Human

Trademarks and Patents Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for

more information.

Limited Uses Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST,

the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no

force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for

Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.